Han E, et al. - Given that sodium glucose co-transporter 2 (SGLT2) inhibitors, like dapagliflozin, have confirmed favorable impacts in patients with type 2 diabetes (T2D), researchers analyzed literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings. For this investigation, the post-marketing surveillance data from a longitudinal prospective study of 2,007 subjects with T2D who were prescribed dapagliflozin (10 mg/day) were investigated. It was assessed that dapagliflozin provided benefits for glycemic control and body weight. Study results suggested that patients in a relatively early stage of diabetes with renal hyperfiltration could be more appropriate for and gain the greatest benefit from treatment with dapagliflozin.